1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-64. https://doi.org/10.3322/caac.21601.
2. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22. https://doi.org/10.1038/s41392-020-0116-z.
3. Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17(2):111-30. https://doi.org/10.1038/s41575-019-0230-y.
4. Andrew AS, Parker S, Anderson JC, et al. Risk Factors for Diagnosis of Colorectal Cancer at a Late Stage: a Population-Based Study. J Gen Intern Med. 2018;33(12):2100-5. https://doi.org/10.1007/s11606-018-4648-7.
5. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78-93. https://doi.org/10.3322/canjclin.54.2.78.
6. Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91(1):119-26. https://doi.org/10.1016/s0092-8674(01)80014-3.
7. Stern-Ginossar N, Weisburd B, Michalski A, et al. Decoding human cytomegalovirus. Science. 2012;338(6110):1088-93. https://doi.org/10.1126/science.1227919.
8. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11(1):1-9. https://doi.org/10.1593/neo.81178.
9. van de Berg PJ, Yong SL, Remmerswaal EB, van Lier RA, ten Berge IJ. Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol. 2012;19(5):772-9. https://doi.org/10.1128/cvi.00011-12.
10. Rahbar A, AlKharusi A, Costa H, et al. Human Cytomegalovirus Infection Induces High Expression of Prolactin and Prolactin Receptors in Ovarian Cancer. Biology (Basel). 2020;9(3). https://doi.org/10.3390/biology9030044.
11. Marinho-Dias J, Sousa H. Cytomegalovirus infection and cervical cancer: from past doubts to present questions. Acta Med Port. 2013;26(2):154-60.
12. Richardson AK, Walker LC, Cox B, et al. Breast cancer and cytomegalovirus. Clin Transl Oncol. 2020;22(4):585-602. https://doi.org/10.1007/s12094-019-02164-1.
13. Lisyany NI, Klyuchnikova AA, Belskaya LN, Lisyany AA, Gnedkova IA. Cytomegaloviruses and malignant brain tumors. Exp Oncol. 2019;41(4):300-3. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13899.
14. Teo WH, Chen HP, Huang JC, Chan YJ. Human cytomegalovirus infection enhances cell proliferation, migration and upregulation of EMT markers in colorectal cancer-derived stem cell-like cells. Int J Oncol. 2017;51(5):1415-26. https://doi.org/10.3892/ijo.2017.4135.
15. Okedele OO, Nelson HH, Oyenuga ML, Thyagarajan B, Prizment A. Cytomegalovirus and cancer-related mortality in the national health and nutritional examination survey. Cancer Causes Control. 2020;31(6):541-7. https://doi.org/10.1007/s10552-020-01296-y.
16. Bhattacharya S, Dunn P, Thomas CG, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015. https://doi.org/10.1038/sdata.2018.15.
17. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884-i90. https://doi.org/10.1093/bioinformatics/bty560.
18. McIver LJ, Abu-Ali G, Franzosa EA, et al. bioBakery: a meta'omic analysis environment. Bioinformatics. 2018;34(7):1235-7. https://doi.org/10.1093/bioinformatics/btx754.
19. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9. https://doi.org/10.1093/bioinformatics/btp352.
20. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-30. https://doi.org/10.1093/bioinformatics/btt656.
21. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https://doi.org/10.1186/s13059-014-0550-8.
22. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284-7. https://doi.org/10.1089/omi.2011.0118.
23. Eide PW, Bruun J, Lothe RA, Sveen A. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci Rep. 2017;7(1):16618. https://doi.org/10.1038/s41598-017-16747-x.
24. Liu CJ, Hu FF, Xia MX, et al. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771-2. https://doi.org/10.1093/bioinformatics/bty411.
25. Miao YR, Zhang Q, Lei Q, et al. ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy. Adv Sci (Weinh). 2020;7(7):1902880. https://doi.org/10.1002/advs.201902880.
26. Cantalupo PG, Katz JP, Pipas JM. Viral sequences in human cancer. Virology. 2018;513:208-16. https://doi.org/10.1016/j.virol.2017.10.017.
27. Chen HP, Jiang JK, Chen CY, et al. Human cytomegalovirus preferentially infects the neoplastic epithelium of colorectal cancer: a quantitative and histological analysis. J Clin Virol. 2012;54(3):240-4. https://doi.org/10.1016/j.jcv.2012.04.007.
28. Chen HP, Jiang JK, Lai PY, et al. Tumoral presence of human cytomegalovirus is associated with shorter disease-free survival in elderly patients with colorectal cancer and higher levels of intratumoral interleukin-17. Clin Microbiol Infect. 2014;20(7):664-71. https://doi.org/10.1111/1469-0691.12412.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013.
30. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39(1):11-26. https://doi.org/10.1016/j.immuni.2013.07.008.
31. McSharry BP, Avdic S, Slobedman B. Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: roles in immunomodulation. Viruses. 2012;4(11):2448-70. https://doi.org/10.3390/v4112448.
32. Dumortier J, Streblow DN, Moses AV, et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol. 2008;82(13):6524-35. https://doi.org/10.1128/jvi.00502-08.
33. Fiorentini S, Luganini A, Dell'Oste V, et al. Human cytomegalovirus productively infects lymphatic endothelial cells and induces a secretome that promotes angiogenesis and lymphangiogenesis through interleukin-6 and granulocyte-macrophage colony-stimulating factor. J Gen Virol. 2011;92(Pt 3):650-60. https://doi.org/10.1099/vir.0.025395-0.
34. Li J, Sun R, Tao K, Wang G. The CCL21/CCR7 pathway plays a key role in human colon cancer metastasis through regulation of matrix metalloproteinase-9. Dig Liver Dis. 2011;43(1):40-7. https://doi.org/10.1016/j.dld.2010.05.013.
35. Nakatsumi H, Matsumoto M, Nakayama KI. Noncanonical Pathway for Regulation of CCL2 Expression by an mTORC1-FOXK1 Axis Promotes Recruitment of Tumor-Associated Macrophages. Cell Rep. 2017;21(9):2471-86. https://doi.org/10.1016/j.celrep.2017.11.014.
36. Chun E, Lavoie S, Michaud M, et al. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. 2015;12(2):244-57. https://doi.org/10.1016/j.celrep.2015.06.024.
37. Zha H, Wang X, Zhu Y, et al. Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. Cancer Immunol Res. 2019;7(2):193-207. https://doi.org/10.1158/2326-6066.Cir-18-0272.
38. Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013;341(1):80-96. https://doi.org/10.1016/j.canlet.2013.01.042.
39. Liu X, Lin K, Huang X, et al. Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis. J Cancer Res Clin Oncol. 2020;146(3):555-68. https://doi.org/10.1007/s00432-019-03092-x.
40. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4. https://doi.org/10.1126/science.1129139.
41. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-8. https://doi.org/10.1200/jco.2010.30.5425.
42. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-51. https://doi.org/10.1200/jco.2008.19.6147.
43. Nagalla S, Chou JW, Willingham MC, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013;14(4):R34. https://doi.org/10.1186/gb-2013-14-4-r34.
44. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28-50. https://doi.org/10.1111/j.0105-2896.2006.00420.x.
45. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 2007;67(18):8865-73. https://doi.org/10.1158/0008-5472.Can-07-0767.
46. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther. 2012;12(10):1383-97. https://doi.org/10.1517/14712598.2012.707184.
47. Cortese N, Soldani C, Franceschini B, et al. Macrophages in Colorectal Cancer Liver Metastases. Cancers (Basel). 2019;11(5). https://doi.org/10.3390/cancers11050633.
48. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445-55. https://doi.org/10.1038/nature12034.
49. Passardi A, Canale M, Valgiusti M, Ulivi P. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017;18(6). https://doi.org/10.3390/ijms18061324.
50. Qian Z, Xuan B, Hong TT, Yu D. The full-length protein encoded by human cytomegalovirus gene UL117 is required for the proper maturation of viral replication compartments. J Virol. 2008;82(7):3452-65. https://doi.org/10.1128/jvi.01964-07.
51. Fu YZ, Guo Y, Zou HM, et al. Human cytomegalovirus protein UL42 antagonizes cGAS/MITA-mediated innate antiviral response. PLoS Pathog. 2019;15(5):e1007691. https://doi.org/10.1371/journal.ppat.1007691.
52. Fu YZ, Su S, Gao YQ, et al. Human Cytomegalovirus Tegument Protein UL82 Inhibits STING-Mediated Signaling to Evade Antiviral Immunity. Cell Host Microbe. 2017;21(2):231-43. https://doi.org/10.1016/j.chom.2017.01.001.
53. Kalejta RF, Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc Natl Acad Sci U S A. 2003;100(6):3263-8. https://doi.org/10.1073/pnas.0538058100.
54. Fu YR, Liu XJ, Li XJ, et al. MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a. J Virol. 2015;89(2):1070-82. https://doi.org/10.1128/jvi.01740-14.